Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-25 @ 2:05 AM
NCT ID:
NCT06184360
Eligibility Criteria:
Inclusion Criteria:
* At least 18 years old at the time of their first (index) injection of brolucizumab.
* Had documented neovascular age-related macular degeneration (nAMD) on or within 3 years before the index injection.
* Used only brolucizumab for at least 12 months (± 45 days) after the index injection, with at least 1 brolucizumab injection given within the first 6 months after the index injection and at least 1 additional brolucizumab injection given at 6-12 months after the index injection.
Exclusion Criteria:
* Had received any other anti-VEGF agent between the index injection and 12-month follow-up.
* Lacked information about the laterality of disease at the time of the index injection.
* Lacked visual acuity assessments on or within 30 days before the index injection or at 6, 9, and 12 months after the index injection (all of the latter ± 45 days).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06184360
Study Brief:
Protocol Section:
NCT06184360